New Malaria Drug Shows Positive Results

☞ | View the text of this post. Exclusively available to ASQ Members.

The plasmodium parasite GlaxoSmithKline (GSK) and Medicines for Malaria Venture (MMV) have announced positive results of the phase III global program to evaluate the efficacy and safety of tafenoquine in treating plasmodium vivax (P. vivax) malaria.

Tafenoquine is an investigational medicine which is being developed for the treatment and relapse prevention (radical cure) of plasmodium vivax (P. vivax) malaria, a form of the disease caused by one of several species of plasmodium parasites known to infect

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *